Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14796733 | 0.82 | CTSK (0.53) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL417361 | 0.82 | CTSK (0.53) | CTSKCTSLCTSSSYKTRPM8 | |
| SCHEMBL15271790 | 0.82 | CTSK (0.53) | CTSKCTSLCTSSSYKTRPM8 | |
| SCHEMBL416706 | 0.82 | CTSK (0.53) | CTSKCTSLCTSSSYKTRPM8 | |
| SCHEMBL25949256 | 0.82 | CTSK (0.58) | CTSKCTSLCTSSCTSBTRPM8 | |
| SCHEMBL13489693 | 0.82 | CTSK (0.58) | CTSKCTSLCTSSCTSBTRPM8 | |
| SCHEMBL3747223 | 0.81 | CTSK (0.46) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL8242655 | 0.81 | TRPM8 (0.56) | CTSKCTSLCTSSCTSBTRPM8 | |
| SCHEMBL8243623 | 0.81 | TRPM8 (0.56) | CTSKCTSLCTSSCTSBTRPM8 | |
| SCHEMBL14509699 | 0.81 | CTSK (0.52) | CTSKCTSLCTSSCTSBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7834051-B2 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | AR, NR5A1, SHBG | CTSK 4596/4885CTSL 4770/4885CTSS 4628/4885 |
| US-20090042967-A1 | Cyclic amine compounds | SHBG, FSHR, ACP3 | CTSK 2063/4885CTSL 1603/4885CTSS 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.